BRIEF published on 04/25/2025 at 07:05, 1 year 6 months ago BB Biotech T1 2025 : ajustements de portefeuille dans un contexte de marché volatil Volatilité Du Marché Portefeuille D'investissement BB Biotech Secteur Biotechnologique Approbations De La FDA
PRESS RELEASE published on 04/25/2025 at 07:00, 1 year 6 months ago EQS-Adhoc: BB Biotech AG publishes its interim report BB Biotech AG publishes its interim report covering the first three months of 2025 revealing a net loss of CHF 241 mn. More information at report.bbbiotech.ch/Q125 Financial Results Investment Company BB Biotech AG Interim Report Business Activities
PRESS RELEASE published on 04/25/2025 at 07:00, 1 year 6 months ago BB Biotech Q1 2025: Sharpened portfolio focus amid continued market volatility BB Biotech AG reports net loss in Q1 2025 due to market volatility. Portfolio focus on innovative biotech companies above USD 1 bn. Details on exits and regulatory milestones Market Volatility BB Biotech AG Biotech Companies Q1 2025 Portfolio Focus
BRIEF published on 03/19/2025 at 17:50, 1 year 7 months ago BB Biotech AG Shareholders Approve Dividend and Re-Elect Board Investment Strategy Dividend Board Re-election BB Biotech AGM 2025
BRIEF published on 03/19/2025 at 17:50, 1 year 7 months ago Les actionnaires de BB Biotech AG approuvent le dividende et réélisent le conseil d'administration Dividende Stratégie D'investissement Réélection Du Conseil D'administration BB Biotech Assemblée Générale Annuelle 2025
PRESS RELEASE published on 03/19/2025 at 17:45, 1 year 7 months ago Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share Shareholders at BB Biotech AG’s AGM approve dividend of CHF 1.80 per share and all board proposals. Re-elected board members for another term Shareholders Dividend AGM BB Biotech AG Board Proposals
BRIEF published on 02/21/2025 at 07:05, 1 year 8 months ago BB Biotech AG Releases 2024 Annual Report Dividend Proposal Net Profit BB Biotech AG Biotechnology Sector 2024 Annual Report
BRIEF published on 02/21/2025 at 07:05, 1 year 8 months ago BB Biotech AG publie son rapport annuel 2024 Bénéfice Net Proposition De Dividende BB Biotech SA Rapport Annuel 2024 Secteur De La Biotechnologie
BRIEF published on 02/21/2025 at 07:05, 1 year 8 months ago BB Biotech Navigates Biotech Sector's Early Recovery in 2024 Investment Strategy 2024 Financial Performance BB Biotech Regulatory Milestones Biotech Recovery
BRIEF published on 02/21/2025 at 07:05, 1 year 8 months ago BB Biotech navigue dans la reprise précoce du secteur biotechnologique en 2024 Stratégie D'investissement Résultats Financiers 2024 Biotechnologie BB Reprise De La Biotechnologie Étapes Réglementaires Importantes
Published on 10/29/2026 at 22:01, 3 hours 50 minutes ago Pinetree Capital Announces Unaudited Financial Results for the Period Ended September 30, 2026
Published on 10/29/2026 at 21:30, 4 hours 21 minutes ago Shelfie Announces Amendments to Previously Announced Acquisition of Aspect
Published on 10/29/2026 at 18:30, 7 hours 21 minutes ago Kidoz Inc. Appoints Derek Sentner as Chief Revenue Officer
Published on 10/29/2026 at 16:05, 9 hours 46 minutes ago SouthGobi Announces Date of Special Meeting of Shareholders and The Record Date
Published on 10/29/2026 at 22:25, 3 hours 25 minutes ago SFC Energy continues strong, profitable growth in the first nine months of 2026 – preliminary figures – earnings guidance raised again
Published on 10/29/2026 at 22:21, 3 hours 30 minutes ago EQS-Adhoc: SFC Energy AG raises full-year 2026 earnings guidance again
Published on 10/29/2026 at 21:29, 4 hours 22 minutes ago 2CRSi SA: Publication of the consolidated annual results and the 2025-2026 Annual Financial Report postponed to 30 October 2026
Published on 10/29/2026 at 21:29, 4 hours 22 minutes ago 2CRSi SA: Report de la publication des résultats annuels consolidés et du Rapport Financier Annuel 2025-2026 au 30 octobre 2026
Published on 10/29/2026 at 21:20, 4 hours 31 minutes ago 2CRSi SA: 2CRSi publie les conclusions de l'expert indépendant mandaté à la suite du rapport Grizzly Research et apporte des précisions sur plusieurs communications antérieures
Published on 10/29/2026 at 18:02, 7 hours 49 minutes ago TF1 9M 2026 results - Consolidated financial statements and appendix
Published on 10/29/2026 at 18:02, 7 hours 49 minutes ago Résultats TF1 9M 2026 - Comptes consolidés et annexes aux comptes
Published on 10/29/2026 at 18:00, 7 hours 51 minutes ago GUILLEMOT CORPORATION: THIRD-QUARTER 2026 TURNOVER / Successful new product launches and acceleration of international commercial partnerships
Published on 10/29/2026 at 18:00, 7 hours 51 minutes ago GUILLEMOT CORPORATION : CHIFFRE D’AFFAIRES TROISIEME TRIMESTRE 2026 / Succès des nouveaux lancements et accélération des partenariats commerciaux internationaux
